BioVentrix Releases Results of Revivent™ Impact on Mitral Regurgitation

26 November 2015

Retrospective sub-study demonstrates impact of ventricular reshaping on mitral regurgitation patients.

BioVentrix Releases Results of Revivent™ Impact on Mitral Regurgitation

San Ramon, CA, November 23, 2015 - BioVentrix, announced that it has completed an analysis of patients with mitral regurgitation who were treated with its Revivent ventricular volume reduction and reshaping technology. 

The Revivent system is a novel, less invasive therapy designed to treat patients suffering from ischemic cardiomyopathy heart failure. Mitral regurgitation (MR) affects 1.6-2.8 million people in the US1 and is widespread in the ischemic heart failure population.
An estimated 40 percent of patients with heart 
failure have a moderate-to-severe ischemic or functional form of MR which originates from ventricular dysfunction2.
Although less 
invasive therapies are currently utilized to treat the valvular and vascular components of heart failure, no proven therapy exists to address the ventricular origin of ischemic mitral regurgitation.
BioVentrix investigated the impact of its Revivent therapy on this patient population 
in a retrospective sub-study analysis of its broader safety and efficacy trial in 7 EU centers.

With a large underserved market available, BioVentrix intends to expand its European clinical trial in the coming year to include a more focused evaluation of the use of Revivent to treat mitral regurgitation.

Click to read the full press release and learn more about the Revivent System and the LIVE Procedure  :

« Go back